Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01991327
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Phase 3
Completed
- Conditions
- Secondary Hypogonadism
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT01993225
Comparison of Two Formulations of Androxal
Phase 1
Completed
- Conditions
- Bioequivalence
- Interventions
- Drug: 12.5 mg Androxal Formulation ADrug: 25 mg Androxal Formulation ADrug: 12.5 mg Androxal Formulation BDrug: 25 mg Androxal Formulation B
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT01984398
- Locations
- 🇺🇸
Clinical Pharmacology of miami, Miami, Florida, United States
Open-Label Extension Study to ZPE-202
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2014-02-07
- Lead Sponsor
- Repros Therapeutics Inc.
- Registration Number
- NCT01961908
Comparison of Two Formulations of Proellex for Vaginal Administration
Phase 1
Completed
- Conditions
- Comparison of 2 Different Formulations of 12 mg Proellex Vaginal Capsules
- Interventions
- Drug: Proellex Formulation ADrug: Proellex Formulation B
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2014-01-24
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT01962805
A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01959685
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function
Phase 1
Completed
- Conditions
- Secondary Hypogonadism
- Interventions
- Drug: Androxal 25 mg
- First Posted Date
- 2013-08-16
- Last Posted Date
- 2014-01-24
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT01923870
Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function
Phase 1
Completed
- Conditions
- Secondary Hypogonadism
- Interventions
- Drug: Androxal 25 mg
- First Posted Date
- 2013-08-16
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT01923857
An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism
- First Posted Date
- 2012-12-03
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT01739582
Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200
Phase 2
Completed
- Conditions
- Uterine Fibroids
- Interventions
- Drug: Proellex 12 mgDrug: Proellex 24 mg
- First Posted Date
- 2012-12-03
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01739621
© Copyright 2025. All Rights Reserved by MedPath